GlassScriptPhysician profile
Bilal Salame
NPI 1265850473
$3,953.92
in general payments reported to CMS, 2019-2025
43 companies · $686 in 2025
The $686 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $265 · 2021: $431 · 2022: $807 · 2023: $520 · 2024: $957 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,572 · Consulting Fee: $525 · Education: $66.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,571.89 |
| Consulting Fee | $525.00 |
| Education | $66.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $736.65 | 2020-2024 | Imfinzi, Calquence |
| Daiichi Sankyo INC. | $348.26 | 2020-2025 | Enhertu |
| Pfizer INC. | $282.76 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $237.26 | 2019 | |
| Lilly USA, LLC | $231.81 | 2020-2025 | Verzenio, Jaypirca |
| Merck Sharp & Dohme LLC | $190.06 | 2020-2025 | Welireg, Keytruda, Keytruda Qlex |
| Seagen INC. | $187.91 | 2020-2023 | Tukysa, Padcev |
| Novartis Pharmaceuticals Corporation | $184.67 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $146.41 | 2022-2023 | |
| Janssen Biotech, INC. | $143.59 | 2022-2025 | Carvykti, Rybrevant |
| Eisai INC. | $112.99 | 2022-2025 | |
| Incyte Corporation | $81.58 | 2025 | Jakafi, Monjuvi |
| Astellas Pharma US INC | $75.71 | 2020-2025 | Vyloy |
| Pharmacosmos Therapeutics INC. | $65.47 | 2022-2023 | Monoferric |
| Regeneron Healthcare Solutions, INC. | $63.26 | 2023-2025 | Lynozyfic, Libtayo |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bilal Salame listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.